| # | Drug | Count |
|---|---|---|
| 0 | NIVOLUMAB | 16 |
| 1 | IPILIMUMAB | 15 |
| 2 | PEMBROLIZUMAB | 10 |
| 3 | CARBOPLATIN | 3 |
| 4 | PACLITAXEL | 2 |
| 5 | PACLITAXEL (AIBUMIN-BOUND) | 2 |
| 6 | PEMETREXED | 2 |
| 7 | PEMETREXED DISODIUM | 2 |
| 8 | CISPLATIN | 1 |
| 9 | CYCLOPHOSPHAMIDE | 1 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | IPILIMUMAB | 15 | 0.0003 |
| 1 | TREMELIMUMAB | 1 | 0.0002 |
| 2 | NIVOLUMAB | 16 | 0.0002 |
| 3 | ENFORTUMAB VEDOTIN | 1 | 0.0001 |
| 4 | VIBEGRON | 1 | 0.0001 |
| 5 | PEMBROLIZUMAB | 10 | 0.0001 |
| 6 | PEMETREXED DISODIUM | 2 | 0.0001 |
| 7 | DURVALUMAB | 1 | 0.0000 |
| 8 | LENVATINIB | 1 | 0.0000 |
| 9 | OLMESARTAN MEDOXOMIL | 1 | 0.0000 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | CTLA-4-directed Blocking Antibody [EPC] | 16 | 0.0003 |
| 1 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 25 | 0.0003 |
| 2 | Programmed Death Ligand-1 Blocker [EPC] | 1 | 0.0000 |
| 3 | beta3-Adrenergic Agonist [EPC] | 1 | 0.0000 |
| 4 | Platinum-based Drug [EPC] | 4 | 0.0000 |
| 5 | Microtubule Inhibitor [EPC] | 2 | 0.0000 |
| 6 | Folate Analog Metabolic Inhibitor [EPC] | 2 | 0.0000 |
| 7 | Alkylating Drug [EPC] | 1 | 0.0000 |
| 8 | Kinase Inhibitor [EPC] | 1 | 0.0000 |